Feb 11, 2015

SCMR Conference in Nice


Center Post doc. Kristin McLeod presented her work on ARVC at the 
Society of Cardiovascular Magnetic Resonance conference in Nice last weekend.

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by fatty and fibrotic replacement of cardiac tissue, which ultimately affects the structure, function and electrical propagation of the ventricles. Diagnosis of ARVC is challenging and is currently guided by the 2010 Task force criteria (2010TFC), which includes criteria identified from imaging, ECG and family history.

Her poster was titled: "Statistical analysis on ventricular shape of ARVC patients and correlation with clinical diagnostic indices." and was presented on Saturday February 7th.

Posted by: Anonymous
Kristin McLeod in Nice, France.
A model of the heart.
Kristin in front of her poster titled "Statistical analysis on ventricular shape of ARVC patients and correlation with clinical diagnostic indices".


A short ARVC project description by Kristin McLeod:

According to the latest criteria for the diagnosis of ARVC, the diagnosis relies on demonstrating structural, functional AND electrophysiological abnormalities. From a computational point of view we can model the structure of the heart from medical images by extracting surface models to represent the endocardial and epicardial walls, we can analyse the function by studying cardiac motion, and we can analyse the electrophysiology of the heart by studying the electrical propagation through the ventricles.

In terms of therapy planning for ARVC patients, the main challenge is to determine which patients are at risk of sudden cardiac death and heart failure to determine who will benefit most from a given method of treatment. Risk stratification for ICD implantation is dependent on current symptoms, so patients without severe VT or dysfunction would be characterised and low-risk, patients with early onset of structurally sever disease and unsustained VT would be moderate risk and patients with sustained VT that are hemodynamically unstable would be high risk.

The low risk group would be ruled as unjustified for ICD implantation, the moderate group would be considered on a case-by-case basis and the high risk group would be considered mandatory for implantation. Therefore, the decision making is based on the severity of the symptoms. A key difficulty though is in the moderate group that is taken on a case-by-case basis.

Knowing which patients are likely to develop to the high risk group is not so clear. To address this point, it’s important to understand the evolution of the disease. Based on the key stages of the disease, we are interested to know for a given patient first of all, which stage they are currently in, based on structural, functional and electrophysiological data.

Center for Cardiological Innovation